Gene BRCA1/2 mutation in prostate cancer patients: clinical administration aspects
https://doi.org/10.17650/1726-9776-2016-12-2-80-83
Abstract
The cases of the uncommon malignant disease state can take place in patients with the prostate cancer. This disease may appear at a young age and the level of the PSA may be normal (to 4 ng / ml), and also the negative clinical prognosis, due to the resistance to standard medical treatment, can take place. In the literature review there is a data on patients’ carrier status of gene BRCA1 / 2 mutation. There are 2 % of such patients and the program of the target screening of the prostate cancer and the special treatment regimen for them should be developed. According to the mechanism of action of the platinum-based drugs and the data from the studies on treatment of the BRCA1 / 2-dependent ovarian cancer in women, where the high sensitivity to the platinum-based drugs in patients with the mutations of the reparation genes of the deoxyribonucleic acid by the homologous recombination was validated, we supposed, that the defects of the deoxyribonucleic acid reparation in patients with the metastatic castration-resistant prostate cancer also might be highly sensitive to the platinum-based drugs.
About the Author
P. V. Koposov
European Medical Center; 35 Shchepkina St., Moscow, 129090, Russia
Russian Federation
Russian Federation
References
1. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52(3):154–79.
2. Baca S.C., Prandi D., Lawrence M.S. et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153(3):666–77.
3. Grasso C.S., Wu Y.M., Robinson D.R. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487(7406):239–43.
4. de Bono J.S., Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467(7315):543–9.
5. Beltran H., Yelensky R., Frampton G.M. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013;63(5): 920–6.
6. Farmer H., McCabe N., Lord C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917–21.
7. Bryant H.E., Schultz N., Thomas H.D. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005;434(7035):913–7.
8. Fong P.C., Boss D.S., Yap T.A. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123–34.
9. Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.J Clin Oncol 2015;33(3):244–50.
10. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382–92.
11. Ledermann J., Harter P., Gourley C. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:856.
12. Mateo J., Carreira S., Sandhu S. et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015;373(18):167–708.
13. Castro E., Goh C., Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748–57.
14. Castro E., Goh C., Leongamornlert D. et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 2015;68(2):186–93.
15. Nelson H.D., Pappas M., Zakher B. et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2014;160(4):255–66.
16. Alanee S.R., Glogowski E.A., Schrader K.A. et al. Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. Front Biosci (Elite Ed) 2014;6:15–30.
17. Akbari M.R., Wallis C.J., Toi A. et al. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer 2014;111(6):1238–40.
18. Bancroft E.K., Page E.C., Castro E. et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 2014;66(3):489–99.
19. Mikropoulos C., Castro E., Bancroft E. et al. Identification of men with a genetic predisposition to prostate cancer: targeted screening in men at higher genetic risk and controls. Program and abstracts of the 2014 Genitourinary Cancers Symposium; January 30 – February 1, 2014; San Francisco, California. Abstr. 8.
20. Leongamornlert D., Mahmud N., Tymrakiewicz M. et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012;106(10):1697–701.
21. Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244–50.
22. Yang D., Khan S., Sun Y. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557–65.
23. Robinson D., Van Allen E.M., Wu Y.M. et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215–28.
24. McCabe N., Turner N.C., Lord C.J. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66(16):8109–15.
25. Murai J., Huang S.Y., Das B.B. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72(2):5588–99.
26. Miller K.M., Tjeertes J.V., Coates J. et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010;17(9):1144–51.
27. Chao O.S., Goodman O.B. Jr. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. Mol Cancer Res 2014;12(12):1755–66.
28. Sternberg C.N., Petrylak D.P., Sartor O. et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431–8.
29. Fong P.C., Yap T.A., Boss D.S. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28(15):2512–9.
30. Ceccaldi R., O’Connor K.W., Mouw K.W. et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015;75(4):628–34.
Review
For citations:
Koposov P.V. Gene BRCA1/2 mutation in prostate cancer patients: clinical administration aspects. Cancer Urology. 2016;12(2):80-83. https://doi.org/10.17650/1726-9776-2016-12-2-80-83
Views:
1271
Email this article 